Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iloprost - Bayer HealthCare Pharmaceuticals

Drug Profile

Iloprost - Bayer HealthCare Pharmaceuticals

Alternative Names: BAYQ 6256; Breelib; Ciloprost; E-1030; Endoprost; Ilocit; Iloderm; Ilomedin; Ilomedine; Iloprost inhalation solution; Iloprost power 15 (Ventavis®) - Actelion; Iloprost trometamol; Isoiloprost; SH-401; Ventavis; VR-876 - Vectura; ZK-36375

Latest Information Update: 13 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Actelion Pharmaceuticals; Bayer HealthCare Pharmaceuticals
  • Class Alkynes; Anti-ischaemics; Antiplatelets; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Epoprostenol agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial occlusive disorders; Pulmonary arterial hypertension; Raynaud's disease; Thromboangiitis obliterans
  • Discontinued Pulmonary hypertension

Most Recent Events

  • 01 Jul 2019 Iloprost is not yet available for Pulmonary arterial hypertension in Iceland and Liechtenstein (Inhalation)
  • 24 Jun 2018 Biomarkers information updated
  • 29 Sep 2017 Bayer completes a phase I/II trial in Pulmonary-hypertension in Austria, Germany (NCT02032836)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top